Примери за използване на Each member state where на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
If traders do not register for MOSS,they should register for VAT in each Member State where the consumer of the services is established.
The MAH shall ensure that in each Member State where Cerdelga is marketed, all patients who are prescribed Cerdelga are provided with a patient alert card.
For the purposes of this Article,a trust is considered to be administered in each Member State where the trustees are established”;
The MAH shall ensure that in each Member State where Kanuma is marketed, all healthcare professionals who are expected to use Kanuma have access to the educational material.
From 1 January 2019, a supplier using the Mini One Stop Shop(MOSS) will only have to follow the invoicing rules of the Member State in which he registered for the MOSS,instead of the rules of each Member State where customers are located.
The MAH shall ensure that in each Member State where Palynziq is marketed, all healthcare professionals and patients, carers and observers who are expected to prescribe, use or oversee the administration of Palynziq have access to/are provided with the following educational package.
The information referred to in paragraph 1 shall be held in a central register referred to in Article 30(3)set up by each Member State where the legal arrangement referred to in paragraph 1 is created, administered or operated.";
The MAH shall ensure that in each Member State where Mysimba is marketed, all healthcare professionals who are expected to prescribe Mysimba are provided with a prescriber guide.
Without prejudice to Article 26 of Regulation(EU) 2015/760,Member States shall ensure that an AIFM makes available, in each Member State where it intends to market units or shares of an AIF to retail investors, facilities to perform the following tasks.
The MAH shall ensure that in each Member State where Raplixa is marketed, all healthcare professionals who are expected to use Raplixa are provided with the following educational material.
In this regard and pursuant to Chapter I of Title V of Directive 2006/112/EC of 28 November 2006, on the common system of value added tax, the place of supply shall be deemed to be within the Member State where items shall be delivered andapplicable VAT shall be at the prevailing rate in each Member State where items are to be supplied as per the orders placed.
The MAH shall ensure that in each Member State where Cerdelga is marketed, all healthcare professionals who are expected to prescribe Cerdelga are provided with a prescriber guide.
In this regard and pursuant to Chapter I of Title V of Council Directive 2006/112/EC of 28 November 2006, on the common system of value added tax, the place of supply shall be deemed to be within the Member State of the address where items shall be delivered andapplicable VAT shall be at the prevailing rate in each Member State where items are to be supplied as per the orders placed.
The MAH shall ensure that in each Member State where Solymbic is marketed, all healthcare professionals who are expected to prescribe Solymbic have are provided with the following educational package.
The MAH shall ensure that, following discussions andagreement with the National Competent Authorities in each Member State where Prometax patch is marketed, all physicians who are expected to prescribe Prometax patch are provided with an information pack containing the following elements.
Each Member State where an unaccompanied minor is present shall ensure that a well-trained representative be appointed immediately upon arrival and represents and/or assists the unaccompanied minor with respect to the relevant procedures provided for in this Regulation.
The MAH ensures that, following discussions andagreement with the National Competent Authorities in each Member State where Eylea is marketed, ophthalmological clinics where Eylea is expected to be used are provided with an updated physician information pack containing the following elements.
The MAH shall ensure that in each Member State where Scenesse is marketed, all healthcare professionals who are expected to use the product are provided with the following educational package and trained.
The MAH shall ensure that in each Member State where Atryn is marketed, all healthcare professionals who are expected to prescribe and use Atryn have access to/are provided with the following educational package.
The MAH shall ensure that in each Member State where Farydak is marketed, all patients/carers who are expected to use Farydak have access to/are provided with the following educational package.
The MAH shall ensure that in each Member State where Strensiq is marketed all patients/parents or caregivers who are expected to use Strensiq are provided with the following educational package.
The MAH shall ensure that in each Member State where Ultomiris is marketed, a system aimed to control distribution of Ultomiris beyond the level of routine risk minimisation measures is in place.
The MAH shall ensure that in each Member State where IMLYGIC is marketed, a system aimed to control distribution to IMLYGIC beyond the level of control ensured by routine risk minimisation measures.
The MAH shall ensure that in each Member State where Alofisel is marketed, all healthcare professionals who are expected to handle and administer Alofisel have access to the educational package for health professionals.
(b) The undertaking must ensure that at least in each Member State where its debt securities are officially listed all the facilities and information necessary to enable holders to exercise their rights are available.
The MAH shall ensure that in each Member State where Zynteglo is marketed, a system aimed to control distribution to Zynteglo beyond the level of control ensured by routine risk minimisation measures.
The MAH shall ensure that in each Member State where sotagliflozin is marketed, all healthcare professionals and patients/carers who are expected to prescribe, dispense or use the product have access to.
The MAH shall ensure that in each Member State where Rienso is marketed, all healthcare professionals and patients/carers who are expected to use Rienso have access to/are provided with the following educational package.
The MAH shall ensure that in each Member State where Lutathera is marketed, all patients/carers who are expected to be administered Lutathera have access to/are provided with a patient educational material containing.